PTPRC and acute myeloid leukemia: Analysis showed that seven malignant immunophenotypic clusters expressing varying levels of CD45 and markers of hematopoietic progenitors (CD34, CD38) or myelomonocytic differentiation (CD33, CD14, CD11c, CD16, and HLA-DR) typical of AML were differentially abundant between the two subtypes (Fig. 4B, C).